Thorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.
Christopher Schreiber added, “MJBizCon is the largest gathering of cannabis related business professionals in the world and a great opportunity for Akers to continue strategic dialogue with potential partners and broaden its relationships in the Hemp and minor cannabinoid space. I look forward to sharing more information on our growth strategy with investors in the near future.”
About Akers Biosciences Inc
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health related information directly to the patient or clinician in a timely and cost-efficient manner.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include the Company’s expectation regarding the offering and the exercise of the preferred stock warrants, and the risk that the proposed public offering will not be consummated, the need for additional financing, and any risks detailed from time to time in Akers' reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although Akers believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. Akers does not have any obligation to update these forward-looking statements other than as required by law.
Additional information on the company and its products can be found at www.akersbio.com.
Contact:
Investor Relations: Hayden IR
Brett Mass, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com